Adarx Pharmaceuticals Raises $446.3 Million in Upsized US IPO
Adarx Pharmaceuticals Inc., a late-stage developer of gene therapies, raised $446.3 million in an upsized initial public offering that priced at the top of its marketed range.
Read the full story at Bloomberg Markets ↗
ImpactNotable 35/100
Why it mattersRule-based estimate: no strong signals; trust 9/10.
RegionsGlobal
Published3 h ago (Thu, 24 Sep 2026 23:43:53 GMT)
RetrievedFri, 25 Sep 2026 02:00:14 GMT via rss
ClassifiedFri, 25 Sep 2026 02:00:22 GMT by heuristic
AuthorAngel Adegbesan